Immunohistochemical determination of EGFR-tyrosine kinase inhibition in clinical samples.
Malik
Shazli N
SN
Department of Surgery, University of Texas Health Science Center, San Antonio, TX, USA.
Bedolla
Roble G
RG
Hidalgo
Manuel
M
Brattain
Michael G
MG
Kreisberg
Jeffrey I
JI
D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001706:Biopsy; D004791:Enzyme Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D066246:ErbB Receptors / Q000037:antagonists & inhibitors* / Q000378:metabolism; D006416:Hematoxylin; D006801:Humans; D007124:Immunoenzyme Techniques; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors* / Q000378:metabolism; D009369:Neoplasms / Q000188:drug therapy / Q000201:enzymology / Q000473:pathology; D016612:Paraffin Embedding; D010766:Phosphorylation / Q000187:drug effects; D011499:Protein Processing, Post-Translational / Q000187:drug effects*; D013048:Specimen Handling; D013194:Staining and Labeling
D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors; D009363:Neoplasm Proteins; D066246:ErbB Receptors; D006416:Hematoxylin